AORT:NYE-Artivion Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 13.31

Change

0.00 (0.00)%

Market Cap

USD 0.75B

Volume

1.45M

Avg Analyst Target

USD 26.50 (+99.10%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AORT Stock Forecast & Price:
Based on the Artivion Inc stock forecasts from 2 analysts, the average analyst target price for Artivion Inc is USD 26.50 over the next 12 months. Artivion Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Artivion Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Artivion Inc’s stock price was USD 13.31. Artivion Inc’s stock price has changed by -36.83% over the past week, -40.45% over the past month and 0% over the last year.

About Artivion Inc (AORT:NYE)

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary proced ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

N/A

USD176.31B 21.02 13.22
MDT Medtronic PLC

N/A

USD119.20B 23.17 14.90
SYK Stryker Corporation

N/A

USD80.38B 39.13 26.51
BSX Boston Scientific Corp

N/A

USD58.95B 72.25 25.10
EW Edwards Lifesciences Corp

N/A

USD52.83B 38.74 28.30
ZBH Zimmer Biomet Holdings Inc

N/A

USD22.79B 78.69 18.73
STE STERIS plc

N/A

USD17.68B 46.27 18.88
PHG Koninklijke Philips NV ADR

N/A

USD15.55B 39.80 12.81
BIO Bio-Rad Laboratories Inc

N/A

USD12.49B 3.61 -5.29
BIO-B Bio-Rad Laboratories Inc

N/A

USD12.14B 3.59 -5.29

ETFs Containing AORT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.75B 36% F 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 422.62 13% F 2% F
Price/Book Ratio 2.86 55% F 28% F
Price / Cash Flow Ratio -288.53 97% A+ 95% A
EV/EBITDA 43.78 6% F 4% F
Management Effectiveness  
Return on Equity -5.89% 52% F 21% F
Return on Invested Capital 1.32% 53% F 33% F
Return on Assets -0.33% 50% F 20% F
Debt to Equity Ratio 102.25% 8% F 35% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 18.28 3% F 1% F
Short Percent 12.40% 9% F 25% F
Beta 1.32 19% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector